Table 1.
Summary of the main studies evaluating tocilizumab for treatment of critically ill COVID-19 patients.
| Authors | Dosage | No. Pt. | Main Results |
|---|---|---|---|
| Xu et al. [66] | 4–8 mg/kg | 21 | Improvements of clinical, laboratory, and radiologic parameters |
| Perrone et al. [TOCIVID-19] [67] | 8 mg/kg | 301 | Decrease of 30-day mortality |
| Price et al. [68] | 8 mg/kg | 239 | Decrease of inflammatory biomarkers and survival prolongation |
| Toniati et al. [69] | 8 mg/kg | 100 | Quick and prolonged clinical improvement |
| Eimer et al. [70] | 8 mg/kg | 29 | Shortening of hospital stay |
| Potere et al. [71] | 324 mg | / | Decrease of mortality |
| Gupta et al. [73] | 8 mg/kg | 3924 | Decrease of death risk |
| Hermine et al. [74] | 8 mg/kg | 64 | No change in 28-day mortality |
| Okoh et al. [75] | 8 mg/kg | 77 | No change in overall survival |
| Campochiaro et al. [76] | 400 mg | 65 | No change in 28-day mortality |
| Stone et al. [79] | 8 mg/kg | 243 | No change in intubation risk and day 14 mortality |
| Salama et al. [80] | 8 mg/kg | 389 | No change in overall survival |
| Gordon et al. [REMAP-CAP] [81] | 8 mg/kg | 353 | Prolongation of 90-day survival |
| Rosas et al. [COVACTA] [82] | 8 mg/kg | 294 | No change in day 28 mortality |